Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board